Zai adds second bispecific to pipeline via Regeneron deal

In Zai’s latest deal giving it local rights to a therapeutic developed in the West, the Shanghai-based biotech has partnered with Regeneron for REGN1979, a bispecific antibody that is in Phase II testing to treat B cell non-Hodgkin lymphoma.

Zai Lab Ltd. (NASDAQ:ZLAB) gained rights in mainland China, Taiwan, Hong Kong and Macau to the antibody targeting CD20 and CD3. The deal covers oncology indications not limited to B-NHL; REGN1979 has Orphan Drug designation from FDA to treat follicular lymphoma and diffuse large B cell lymphoma (DLBCL)...